SGMO - Sangamo Therapeutics rises 5% after hours following Q4 earnings

Sangamo Therapeutics' (NASDAQ:SGMO) Q4 2021 beats on the top and bottom lines has propelled the stock 5% higher in after-hours trading. The company's net loss in the quarter narrowed ~8% to ~$37.5M. Basic and diluted net loss per share was -$0.26, compared to -$0.29 in Q4 2020. Revenue increased ~8% to $28M. Total operating expenses decreased 2% to ~$67.9M The company ended the year with $464.7M in cash. Just today, Seeking Alpha contributor Avisol Capital Partners issued a hold rating on Sangamo (SGMO).

For further details see:

Sangamo Therapeutics rises 5% after hours following Q4 earnings